
|Articles|January 15, 2003
IOP-lowering efficacy of bimatoprost, latanoprost weighed
Bimatoprost 0.03% (Lumigan, Allergan) offers more efficacy than latanoprost 0.005% (Xalatan, Pharmacia) for lowering elevated IOP and is similarly well tolerated, according to the results of a 6-month, multicenter, randomized, double-masked study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Corza Medical announces launch of the SensorTek ROP Kit
2
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
3
Defining Retinal Vascular Diseases AMD, DME, RVO
4
EyePoint receives second consecutive positive recommendation from DSMC
5


















































.png)


